Peter Mortimer

6PUBLICATIONS
76CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Dec 05, 2023
Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.

Susanne A Gatz, Anne C Harttrampf, Caroline Brard

|Mar 05, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.

Atish D Choudhury, Celestia S Higano, Johann S de Bono

|Sep 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).

Haider Mahdi, Navid Hafez, Deborah Doroshow

|May 12, 2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Seung Tae Kim, Simon A Smith, Peter Mortimer

|Jul 19, 2019
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.

Jeeyun Lee, Seung Tae Kim, Kyung Kim

Pageof 1

Frequent Collaborators

9 joint publications

Young Saing Kim

2 joint publications

Nicolas André

2 joint publications

Emilie De Carli

2 joint publications

Souad Nebchi